PL2991988T3 - Pochodne pirolo[2,3-d]pirymidyny jako agoniści receptora cb2 - Google Patents

Pochodne pirolo[2,3-d]pirymidyny jako agoniści receptora cb2

Info

Publication number: PL2991988T3
Authority: PL; Poland
Prior art keywords: pyrrolo; receptor agonists; pyrimidine derivatives; pyrimidine; derivatives
Prior art date: 2013-05-02

Application number

PL14720136T

Other languages

English (en)

Inventor

Uwe Grether

Atsushi Kimbara

Matthias Nettekoven

Stephan Roever

Mark Rogers-Evans

Tanja Schulz-Gasch

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-02

Filing date

2014-04-29

Publication date

2017-10-31

2014-04-29 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2017-10-31 Publication of PL2991988T3 publication Critical patent/PL2991988T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL14720136T 2013-05-02 2014-04-29 Pochodne pirolo[2,3-d]pirymidyny jako agoniści receptora cb2 PL2991988T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP13166296		2013-05-02
EP14720136.2A EP2991988B1 (en)	2013-05-02	2014-04-29	Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
PCT/EP2014/058648 WO2014177527A1 (en)	2013-05-02	2014-04-29	Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists

Publications (1)

Publication Number	Publication Date
PL2991988T3 true PL2991988T3 (pl)	2017-10-31

Family

ID=48190401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14720136T PL2991988T3 (pl)	2013-05-02	2014-04-29	Pochodne pirolo[2,3-d]pirymidyny jako agoniści receptora cb2

Country Status (34)

Country	Link
US (1)	US9580435B2 (pl)
EP (1)	EP2991988B1 (pl)
JP (1)	JP6454689B2 (pl)
KR (1)	KR20160002857A (pl)
CN (1)	CN105164133B (pl)
AR (1)	AR096153A1 (pl)
AU (1)	AU2014261546B2 (pl)
BR (1)	BR112015027394A8 (pl)
CA (1)	CA2907691A1 (pl)
CL (1)	CL2015003196A1 (pl)
CR (1)	CR20150555A (pl)
CY (1)	CY1119114T1 (pl)
DK (1)	DK2991988T3 (pl)
EA (1)	EA028123B1 (pl)
ES (1)	ES2635632T3 (pl)
HR (1)	HRP20171099T1 (pl)
HU (1)	HUE035333T2 (pl)
IL (1)	IL242162B (pl)
LT (1)	LT2991988T (pl)
MA (1)	MA38555B1 (pl)
MX (1)	MX373855B (pl)
MY (1)	MY182237A (pl)
NZ (1)	NZ712030A (pl)
PE (1)	PE20160039A1 (pl)
PH (1)	PH12015502409A1 (pl)
PL (1)	PL2991988T3 (pl)
PT (1)	PT2991988T (pl)
RS (1)	RS56313B1 (pl)
SG (1)	SG11201509029PA (pl)
SI (1)	SI2991988T1 (pl)
TW (1)	TWI680129B (pl)
UA (1)	UA116801C2 (pl)
WO (1)	WO2014177527A1 (pl)
ZA (1)	ZA201507008B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3483163T (lt)	2013-09-06	2021-09-10	F. Hoffmann-La Roche Ag	Triazol[4,5-d]pirimidino dariniai kaip cb2 receptorių antagonistai
MX2017005857A (es) *	2014-11-07	2017-06-26	Hoffmann La Roche	Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2.
CN109311886B (zh)	2016-06-23	2021-11-09	豪夫迈·罗氏有限公司	[1,2,3]三唑并[4,5-d]嘧啶衍生物
AU2017283136C1 (en)	2016-06-23	2021-07-29	F. Hoffmann-La Roche Ag	[1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
WO2017220544A1 (en)	2016-06-23	2017-12-28	F. Hoffmann-La Roche Ag	Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
WO2017220516A1 (en)	2016-06-23	2017-12-28	F. Hoffmann-La Roche Ag	Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
KR20230093251A (ko)	2020-09-10	2023-06-27	프리시릭스 엔.브이.	Fap에 대한 항체 단편
WO2023203135A1 (en)	2022-04-22	2023-10-26	Precirix N.V.	Improved radiolabelled antibody
KR20250034289A (ko)	2022-05-02	2025-03-11	프리시릭스 엔.브이.	사전 표적화

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001234958A1 (en)	2000-02-11	2001-08-20	Bristol-Myers Squibb Company	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CA2479744A1 (en)	2002-03-28	2003-10-09	Paul E. Finke	Substituted 2,3-diphenyl pyridines
DE10219435A1 (de)	2002-05-02	2003-11-13	Bayer Cropscience Ag	Substituierte Pyrazolo-pyrimidin-4-one
TWI270549B (en) *	2002-12-26	2007-01-11	Taisho Pharmaceutical Co Ltd	Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
AR051596A1 (es)	2004-10-26	2007-01-24	Irm Llc	Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
MX2008012400A (es) *	2006-03-30	2008-10-10	Irm Llc	Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
CN101855222A (zh) *	2007-05-10	2010-10-06	通用电气健康护理有限公司	对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
US20090062253A1 (en) *	2007-08-31	2009-03-05	Kalypsys, Inc.	Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2211619A1 (en)	2007-10-18	2010-08-04	Merck Sharp & Dohme Corp.	Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
UA104010C2 (en) *	2008-12-18	2013-12-25	Эли Лилли Энд Компани	Purine compounds
WO2010118367A2 (en)	2009-04-10	2010-10-14	Progenics Pharmaceuticals, Inc.	Antiviral pyrimidines
JP5629324B2 (ja) *	2009-10-15	2014-11-19	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジン化合物
US9321727B2 (en)	2011-06-10	2016-04-26	Hoffmann-La Roche Inc.	Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk)	2011-11-08	2016-05-25	Ф. Хоффманн-Ля Рош Аг	ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
BR112014032996A2 (pt)	2012-07-04	2018-05-15	Hoffmann La Roche	derivados de adamantil como agonistas do receptor de canabinoide 2
MY179412A (en)	2012-12-07	2020-11-05	Hoffmann La Roche	Pyridine-2-amides useful as cb2 agonists
MX2015006036A (es)	2012-12-07	2015-08-07	Hoffmann La Roche	Nuevos derivados de pirazina como agonistas del receptor de carabinoides 2.
EA026669B1 (ru)	2012-12-07	2017-05-31	Ф. Хоффманн-Ля Рош Аг	Производные пиридина
SG11201504122YA (en)	2012-12-07	2015-06-29	Hoffmann La Roche	Pyridine-2-amides useful as cb2 agonists
SG11201507168XA (en)	2013-03-07	2015-10-29	Hoffmann La Roche	Novel pyrazol derivatives
EA027497B1 (ru)	2013-05-02	2017-07-31	Ф. Хоффманн-Ля Рош Аг	Производные пурина в качестве агонистов каннабиноидного рецептора cb2

2014
- 2014-04-29 ES ES14720136.2T patent/ES2635632T3/es active Active
- 2014-04-29 PL PL14720136T patent/PL2991988T3/pl unknown
- 2014-04-29 MA MA38555A patent/MA38555B1/fr unknown
- 2014-04-29 HU HUE14720136A patent/HUE035333T2/en unknown
- 2014-04-29 UA UAA201510730A patent/UA116801C2/uk unknown
- 2014-04-29 EA EA201591939A patent/EA028123B1/ru not_active IP Right Cessation
- 2014-04-29 WO PCT/EP2014/058648 patent/WO2014177527A1/en not_active Ceased
- 2014-04-29 NZ NZ712030A patent/NZ712030A/en unknown
- 2014-04-29 RS RS20170752A patent/RS56313B1/sr unknown
- 2014-04-29 PE PE2015002323A patent/PE20160039A1/es active IP Right Grant
- 2014-04-29 PT PT147201362T patent/PT2991988T/pt unknown
- 2014-04-29 EP EP14720136.2A patent/EP2991988B1/en active Active
- 2014-04-29 CA CA2907691A patent/CA2907691A1/en not_active Abandoned
- 2014-04-29 DK DK14720136.2T patent/DK2991988T3/en active
- 2014-04-29 MY MYPI2015703900A patent/MY182237A/en unknown
- 2014-04-29 KR KR1020157031006A patent/KR20160002857A/ko not_active Ceased
- 2014-04-29 MX MX2015014081A patent/MX373855B/es active IP Right Grant
- 2014-04-29 CN CN201480024215.5A patent/CN105164133B/zh active Active
- 2014-04-29 AU AU2014261546A patent/AU2014261546B2/en not_active Ceased
- 2014-04-29 LT LTEP14720136.2T patent/LT2991988T/lt unknown
- 2014-04-29 HR HRP20171099TT patent/HRP20171099T1/hr unknown
- 2014-04-29 BR BR112015027394A patent/BR112015027394A8/pt not_active IP Right Cessation
- 2014-04-29 SG SG11201509029PA patent/SG11201509029PA/en unknown
- 2014-04-29 JP JP2016511035A patent/JP6454689B2/ja active Active
- 2014-04-29 SI SI201430317T patent/SI2991988T1/sl unknown
- 2014-04-30 AR ARP140101784A patent/AR096153A1/es unknown
- 2014-04-30 TW TW103115663A patent/TWI680129B/zh not_active IP Right Cessation
2015
- 2015-09-21 ZA ZA2015/07008A patent/ZA201507008B/en unknown
- 2015-10-14 CR CR20150555A patent/CR20150555A/es unknown
- 2015-10-16 PH PH12015502409A patent/PH12015502409A1/en unknown
- 2015-10-19 IL IL242162A patent/IL242162B/en active IP Right Grant
- 2015-10-26 US US14/923,186 patent/US9580435B2/en active Active
- 2015-10-30 CL CL2015003196A patent/CL2015003196A1/es unknown
2017
- 2017-07-24 CY CY20171100785T patent/CY1119114T1/el unknown

Also Published As

Publication number	Publication date
DK2991988T3 (en)	2017-08-21
US9580435B2 (en)	2017-02-28
WO2014177527A1 (en)	2014-11-06
PE20160039A1 (es)	2016-01-28
CN105164133A (zh)	2015-12-16
NZ712030A (en)	2021-03-26
MX373855B (es)	2020-03-25
JP2016517874A (ja)	2016-06-20
CA2907691A1 (en)	2014-11-06
HRP20171099T1 (hr)	2017-10-06
EP2991988A1 (en)	2016-03-09
BR112015027394A2 (pt)	2017-07-25
JP6454689B2 (ja)	2019-01-16
SI2991988T1 (sl)	2017-09-29
BR112015027394A8 (pt)	2018-01-30
HUE035333T2 (en)	2018-05-02
MY182237A (en)	2021-01-18
HK1213559A1 (zh)	2016-07-08
EP2991988B1 (en)	2017-05-31
KR20160002857A (ko)	2016-01-08
LT2991988T (lt)	2017-08-10
RS56313B1 (sr)	2017-12-29
AU2014261546A1 (en)	2015-09-24
CL2015003196A1 (es)	2016-06-03
ES2635632T3 (es)	2017-10-04
AU2014261546B2 (en)	2018-01-18
IL242162B (en)	2019-06-30
ZA201507008B (en)	2017-08-30
TW201522343A (zh)	2015-06-16
AR096153A1 (es)	2015-12-09
PH12015502409B1 (en)	2016-02-22
TWI680129B (zh)	2019-12-21
EA028123B1 (ru)	2017-10-31
PT2991988T (pt)	2017-07-25
SG11201509029PA (en)	2015-12-30
UA116801C2 (uk)	2018-05-10
CR20150555A (es)	2015-11-20
EA201591939A1 (ru)	2016-03-31
CY1119114T1 (el)	2018-02-14
MA38555A1 (fr)	2017-09-29
PH12015502409A1 (en)	2016-02-22
MA38555B1 (fr)	2018-04-30
CN105164133B (zh)	2018-02-13
MX2015014081A (es)	2015-12-11
US20160046637A1 (en)	2016-02-18

Publication	Publication Date	Title
PT3483163T (pt)	2021-08-24	Novos derivados de triazolo[4,5-d]pirimidina como antagonistas de receptor cb2
ZA201506570B (en)	2017-02-22	2-phenylimidazo[1,2-a]pyrimidines as imaging agents
SG11201404969YA (en)	2014-10-30	2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
IL242162B (en)	2019-06-30	Pyrrolo [2, 3 –d] pyrimidine derivatives as 2cb receptor agonists
SG11201402197UA (en)	2014-09-26	[1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
IL258231A (en)	2018-05-31	New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
PT2928882T (pt)	2017-03-16	Derivados de pirazina como agonistas do recetor de cb2
EP3038466A4 (en)	2017-01-18	2,2-difluorodioxolo a2a receptor antagonists
IL232304A (en)	2016-02-29	[3,2,1] triazolo [5,4– d] pyrimidine derivatives as cannabinoid receptor type 2 agonists [3,2,1] triazolo [5,4– d] pyrimidine as cannabinoid receptor 2 agonists
IL242160B (en)	2019-06-30	Purine derivatives as 2cb receptor agonists